DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
ACYLINE
2
Protein
Investigational
Unknown
Unknown
Hypogonadism
Gonadotropin-releasing hormone receptor antagonist
ACYLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
S3439D3B35
Molecule Type:
Protein
Molecular Formula:
C80H102ClN15O14
Molecular Weight:
1533.24
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GSK-3117391
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Unknown
GSK-3117391
×
Maximum Phase:
2
First Approval:
None
UNII:
CKA3P0O1VI
Molecule Type:
Small molecule
Molecular Formula:
C22H33N3O4
Molecular Weight:
403.52
AlogP:
3.04
PSA:
100.55
HBD:
3.0
HBA:
#RotB:
9.0
Source:
BLZ945
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Amyotrophic Lateral Sclerosis
Unknown
BLZ945
×
Maximum Phase:
2
First Approval:
None
UNII:
7W3V82OQ0P
Molecule Type:
Small molecule
Molecular Formula:
C20H22N4O3S
Molecular Weight:
398.49
AlogP:
3.56
PSA:
96.37
HBD:
3.0
HBA:
#RotB:
5.0
Source:
VB-201
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative; Psoriasis; Severe Acute Respiratory Syndrome
Monocyte differentiation antigen CD14 inhibitor
VB-201
×
Maximum Phase:
2
First Approval:
None
UNII:
SJ5A8151JO
Molecule Type:
Small molecule
Molecular Formula:
C29H60NO8P
Molecular Weight:
581.77
AlogP:
6.33
PSA:
114.35
HBD:
1.0
HBA:
#RotB:
30.0
Source:
TADOCIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Integrin alpha-IIb/beta-3 antagonist
TADOCIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
R34T642CGV
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEMCIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms
Delta-like protein 4 inhibitor
DEMCIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
SF168W7FW0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RUSALATIDE ACETATE
2
Protein
Investigational
Unknown
Unknown
Radius Fractures
Unknown
RUSALATIDE ACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
9J556O9JPD
Molecule Type:
Protein
Molecular Formula:
C101H155N29O39S
Molecular Weight:
2431.58
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
M9241
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
M9241
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AGANIRSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Unknown
Insulin receptor substrate 1 mRNA antisense inhibitor
AGANIRSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
0N3FY8225K
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUCANTHONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LUCANTHONE
×
Maximum Phase:
2
First Approval:
None
UNII:
FC6D57000M
Molecule Type:
Small molecule
Molecular Formula:
C20H24N2OS
Molecular Weight:
340.49
AlogP:
4.48
PSA:
32.34
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PORGAVIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Hemorrhagic Fever, Ebola
Unknown
PORGAVIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
07EY0HWO2M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INTRON-A
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
INTRON-A
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROGARATINIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Neoplasms; Urinary Bladder Neoplasms
Fibroblast growth factor receptor inhibitor
ROGARATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
98BSN6N516
Molecule Type:
Small molecule
Molecular Formula:
C23H26N6O3S
Molecular Weight:
466.57
AlogP:
2.59
PSA:
107.01
HBD:
2.0
HBA:
#RotB:
6.0
Source:
RETINOIC ACID RECEPTOR .GAMMA.
2
Unknown
Investigational
Unknown
Unknown
Emphysema
Unknown
RETINOIC ACID RECEPTOR .GAMMA.
×
Maximum Phase:
2
First Approval:
None
UNII:
OSD7UB9MEE
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANFIBATIDE
2
Protein
Investigational
Unknown
Unknown
Myocardial Infarction; Purpura, Thrombotic Thrombocytopenic
Platelet glycoprotein Ib alpha chain antagonist
ANFIBATIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
DCG29J773G
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLYCERINATED GERMAN COCKROACH ALLERGENIC EXTRACT
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GLYCERINATED GERMAN COCKROACH ALLERGENIC EXTRACT
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIAGENPUMATUCEL-L
2
Cell
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Unknown
VIAGENPUMATUCEL-L
×
Maximum Phase:
2
First Approval:
None
UNII:
13H90KC831
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SONOLISIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Glioblastoma; Prostatic Neoplasms, Castration-Resistant
PI3-kinase class I inhibitor
SONOLISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
987796874T
Molecule Type:
Small molecule
Molecular Formula:
C29H35NO8
Molecular Weight:
525.6
AlogP:
3.13
PSA:
119.44
HBD:
1.0
HBA:
#RotB:
8.0
Source:
MANITIMUS
2
Small molecule
Investigational
Unknown
Unknown
Graft vs Host Disease; Kidney Diseases
Unknown
MANITIMUS
×
Maximum Phase:
2
First Approval:
None
UNII:
4B135RK2KL
Molecule Type:
Small molecule
Molecular Formula:
C14H10F3N3O2
Molecular Weight:
309.25
AlogP:
3.28
PSA:
96.91
HBD:
2.0
HBA:
#RotB:
4.0
Source:
E7449
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
E7449
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIIB-023
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Nephritis
Tumor necrosis factor ligand superfamily member 12 inhibitor
BIIB-023
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CENPLACEL-L
2
Cell
Investigational
Unknown
Unknown
Sarcoidosis, Pulmonary; Arthritis, Rheumatoid; Crohn Disease
Unknown
CENPLACEL-L
×
Maximum Phase:
2
First Approval:
None
UNII:
OOH12XV6XR
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HGT-1410
2
Enzyme
Investigational
Unknown
Unknown
Unknown
Unknown
HGT-1410
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Enzyme
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OSORESNONTRINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Mental Disorders; Schizophrenia
Unknown
OSORESNONTRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
O9OC34WOAY
Molecule Type:
Small molecule
Molecular Formula:
C16H17N5O2
Molecular Weight:
311.35
AlogP:
1.46
PSA:
85.69
HBD:
1.0
HBA:
#RotB:
3.0
Source:
VILANTEROL .ALPHA.-PHENYL CINNAMATE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
VILANTEROL .ALPHA.-PHENYL CINNAMATE
×
Maximum Phase:
2
First Approval:
None
UNII:
DB71X3OVN2
Molecule Type:
Small molecule
Molecular Formula:
C39H45Cl2NO7
Molecular Weight:
710.7
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
NEPICASTAT
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders; Stress Disorders, Post-Traumatic
Unknown
NEPICASTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
VPG12K4540
Molecule Type:
Small molecule
Molecular Formula:
C14H15F2N3S
Molecular Weight:
295.36
AlogP:
2.64
PSA:
43.84
HBD:
2.0
HBA:
#RotB:
2.0
Source:
CINACIGUAT
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure
Soluble guanylate cyclase activator
CINACIGUAT
×
Maximum Phase:
2
First Approval:
None
UNII:
59K0Y58UAD
Molecule Type:
Small molecule
Molecular Formula:
C36H39NO5
Molecular Weight:
565.71
AlogP:
7.05
PSA:
87.07
HBD:
2.0
HBA:
#RotB:
17.0
Source:
RALMITARONT
2
Small molecule
Investigational
Unknown
Unknown
Psychotic Disorders
Unknown
RALMITARONT
×
Maximum Phase:
2
First Approval:
None
UNII:
QA8MW1Q80P
Molecule Type:
Small molecule
Molecular Formula:
C17H22N4O2
Molecular Weight:
314.39
AlogP:
2.19
PSA:
79.04
HBD:
3.0
HBA:
#RotB:
4.0
Source:
FILOREXANT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major; Diabetic Neuropathies; Sleep Initiation and Maintenance Disorders
Orexin receptor antagonist
FILOREXANT
×
Maximum Phase:
2
First Approval:
None
UNII:
E6BTT8VA5Z
Molecule Type:
Small molecule
Molecular Formula:
C24H25FN4O2
Molecular Weight:
420.49
AlogP:
4.31
PSA:
68.21
HBD:
0.0
HBA:
#RotB:
5.0
Source:
HMPL-453
2
Unknown
Investigational
Unknown
Unknown
Neoplasms; Bile Duct Neoplasms; Mesothelioma
Fibroblast growth factor receptor 1 inhibitor
HMPL-453
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
O-CHLOROACETYLCARBAMOYLFUMAGILLOL
2
Small molecule
Investigational
Unknown
Unknown
Pancreatic Neoplasms
Unknown
O-CHLOROACETYLCARBAMOYLFUMAGILLOL
×
Maximum Phase:
2
First Approval:
None
UNII:
X47GR46481
Molecule Type:
Small molecule
Molecular Formula:
C19H28ClNO6
Molecular Weight:
401.89
AlogP:
2.55
PSA:
89.69
HBD:
1.0
HBA:
#RotB:
6.0
Source:
DCDP
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
DCDP
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GW590735
2
Small molecule
Investigational
Unknown
Unknown
Lipid Metabolism Disorders
Peroxisome proliferator-activated receptor alpha agonist
GW590735
×
Maximum Phase:
2
First Approval:
None
UNII:
QKY617BBX5
Molecule Type:
Small molecule
Molecular Formula:
C23H21F3N2O4S
Molecular Weight:
478.49
AlogP:
5.31
PSA:
88.52
HBD:
2.0
HBA:
#RotB:
7.0
Source:
UK-390957
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
UK-390957
×
Maximum Phase:
2
First Approval:
None
UNII:
W26I0D1D6J
Molecule Type:
Small molecule
Molecular Formula:
C16H20N2O3S2
Molecular Weight:
352.48
AlogP:
2.91
PSA:
72.63
HBD:
1.0
HBA:
#RotB:
6.0
Source:
7-ETHYL-10-HYDROXYCAMPTOTHECIN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Small Cell Lung Carcinoma
DNA topoisomerase I inhibitor
7-ETHYL-10-HYDROXYCAMPTOTHECIN
×
Maximum Phase:
2
First Approval:
None
UNII:
0H43101T0J
Molecule Type:
Small molecule
Molecular Formula:
C22H20N2O5
Molecular Weight:
392.41
AlogP:
2.35
PSA:
101.65
HBD:
2.0
HBA:
#RotB:
2.0
Source:
1
2
…
193
194
195
196
197
198
199
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA